Next Generation MicroLead 2.0 Now Available with the SPRINT® PNS System
06 sept. 2022 08h00 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Sept. 06, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced today the formal introduction of its new MicroLead™ 2.0, designed to enhance the performance of the SPRINT® PNS System. As a...
Peripheral Nerve Stimulation Pioneer Dr. Marc Huntoon Joins SPR Therapeutics as Director of Medical Affairs
02 août 2022 16h23 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Aug. 02, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics is proud to announce the addition of Dr. Marc Huntoon to the company as Director of Medical Affairs. In this role, he will provide...
SPR Therapeutics to Present Clinical Trial and Real-World Findings at ASPN 2022
14 juil. 2022 10h54 HE
|
SPR Therapeutics, Inc.
CLEVELAND, July 14, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced today that two presentations highlighting SPRINT® PNS in treating chronic pain will be featured at the American Society of...
SPR Therapeutics Named a Top Workplace
26 juin 2022 11h00 HE
|
SPR Therapeutics, Inc.
CLEVELAND, June 26, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics has been awarded a Top Workplaces 2022 honor by cleveland.com and The Plain Dealer. The award is based on employee feedback gathered...
SPR Therapeutics Announces 10,000th SPRINT PNS Procedure for Patients Suffering from Life-altering Pain
12 mai 2022 09h00 HE
|
SPR Therapeutics, Inc.
CLEVELAND, May 12, 2022 (GLOBE NEWSWIRE) -- Cleveland based medical device company SPR Therapeutics today announced a key milestone with the 10,000th patient treated using the SPRINT® PNS System....
Real-world Study of SPRINT 60-day Peripheral Nerve Stimulation (PNS) Corroborates Published Clinical Study Results
06 mai 2022 09h24 HE
|
SPR Therapeutics, Inc.
CLEVELAND, May 06, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced the publication of a study that evaluated the real-world impact of 60-day peripheral nerve stimulation (PNS) in the management...
Prolonged Temporary Neurostimulation Treatment Period Offered by the SPRINT® PNS System May Optimize Pain Management Care Pathway While Reducing Healthcare Costs
15 mars 2022 10h31 HE
|
SPR Therapeutics, Inc.
CLEVELAND, March 15, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced publication of a study in the Journal of Pain Research demonstrating how a longer initial treatment period may better...
The PNS Trifecta: All Three SPRINT® PNS System Abstracts Submitted to ASRA 2021 Pain Medicine Meeting Receive President’s Choice Award
18 nov. 2021 12h32 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics has been honored with three President’s Choice Abstract Awards at the 20th Annual ASRA Pain Medicine Meeting taking place November 18-20...
FDA Clearance of an Expanded Indication for the SPRINT® PNS System Now Enables Treatment in Areas of the Head, Neck, and Torso
19 oct. 2021 12h22 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Ohio, Oct. 19, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics® has obtained clearance from the U.S. Food and Drug Administration (FDA) of a broader indication for use for its SPRINT Peripheral...
Multi-center Study Demonstrates Significant Reductions in Postoperative Pain and Opioid Use Following Peripheral Nerve Stimulation Treatment
26 avr. 2021 09h41 HE
|
SPR Therapeutics, Inc.
CLEVELAND, April 26, 2021 (GLOBE NEWSWIRE) -- Results of a multicenter trial recently published in Anesthesiology, the official peer-reviewed journal of the American Society of Anesthesiologists,...